DALLAS, June 13, 2019 (GLOBE NEWSWIRE) -- via OTC
PR WIRE -- Puration, Inc. (PURA) ( â€PURAâ€)
today announced the impending launch of its EVERx CBD Sports Water
production in Texas. EVERx is the leading CBD Infused water
in the sports nutrition market. Launched in 2017 at Arnold
Schwarzenegger’s Annual Arnold Sports Fest, EVERx achieved over $1
million in annual sales in 2018. PURA has targeted $4 million
in sales for 2019 and management has indicated it may increase that
target with the opening of a new EVERx production line in Texas now
that Texas law has cleared the way. Texas Governor Greg
Abbott signed a new law Monday this week legalizing hemp and
hemp-derived products. PURA had prepared production
capacity in Texas in anticipation of Texas passing the bill signed
into law this week and expects to begin production in Texas by the
end of the month of June.
PURA Speculative Buy Recommendation and
$0.25 PPS Target w/Potential to $0.35
Goldman Small Cap Research has released a new
research report recommending PURA as a Speculative BUY with a
$0.25 PPS Target. Goldman Small Cap Research further
reports that the shares of PURA “have the potential to reach the
$0.35 mark.†The report highlights PURA’s growing EVERx CBD
Sports Water sales and the coming introduction of new beverages as
well as the potential for the company to exceed its 2019 sales
targets through the pending doubling of its production capacity and
through planned acquisitions. The report further details
recent updates intended to accelerate the issue of Nouveau
(NOUV) stock to PURA shareholders in a
dividend distribution. Notably, the report points to the
capacity and quality improvements enabled by the addition of a new
team member with exceptional beverage industry professional
experience.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Contact:
Puration, Inc.
Brian Shibley,
[email protected]
(800) 861-1350